
Avantor Inc. (AVTR) Stock Forecast & Price Target
Avantor Inc. (AVTR) Analyst Ratings
Bulls say
Avantor Inc. has demonstrated significant market share gains, securing over $100 million through contract expansions with major pharmaceutical clients, which could enhance volume and profitability through higher fixed cost absorption. The company operates in a robust healthcare sector and is poised for margin expansion that aligns more closely with industry peers, potentially leading to multiple expansion over time. While the near-term growth estimates remain cautious, a strategic focus on cost reductions exceeding $400 million by 2027 is expected to bolster overall financial performance and support a positive long-term outlook.
Bears say
Avantor Inc. has adjusted its FY25 organic revenue growth forecast downward to a range of -2% to 0%, reflecting ongoing customer-specific challenges in the bioprocessing segment and a revenue decline in the second quarter. In addition, the company's second-quarter organic revenues fell 1% to $1.58 billion, accompanied by adjusted EBITDA margins that were below consensus expectations, signaling weakening operational performance. The company also highlighted significant pressures from major customers in the bioprocess sector, which are expected to impact revenues negatively moving forward, particularly if the purchasing slowdown from smaller biotech firms persists.
This aggregate rating is based on analysts' research of Avantor Inc. and is not a guaranteed prediction by Public.com or investment advice.
Avantor Inc. (AVTR) Analyst Forecast & Price Prediction
Start investing in Avantor Inc. (AVTR)
Order type
Buy in
Order amount
Est. shares
0 shares